BioSpace News Archive

Orexo´s partner Gesynta Pharma’s drug candidate GS-248 (OX-MPI) granted Orphan Drug Designation in the US by the FDA for the treatment of systemic sclerosis

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine has been approved by the Brazilian Health Regulatory Agency for emergency use in children from 3 to 5 years old on 13 July.

BeiGene, a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that the U.S. Food and Drug Administration has deferred action on the Biologics License Application for tislelizumab as a second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, provided an update on the dose escalation portion of the TH1902 Phase 1 clinical safety study.

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 28, 2022.

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 4, 2022 , at 8:00 a.m. CDT to review fourth quarter 2022 financial results.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report.

Allos Pharma Inc (“Allos”), a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, announces presentation of “Arbaclofen produces clinically meaningful improvements in individuals with Fragile X” at the 18th NFXF International Fragile X Conference, July 14-17th , 2022.

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.